REFERENCES
- Bourcier T, Thomas F, Borderie V, et al. Bacterial keratitis: Predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003;87:834–838.
- Wong T, Ormonde S, Gamble G, et al. Severe infective keratitis leading to hospital admission in New Zealand. Br J Ophthalmol. 2003;87:1103–1108.
- Bharathi M, Ramakrishnan R, Vasu S, et al. In-vitro efficacy of antibacterials against bacterial isolates from corneal ulcers. Indian J Ophthalmol. 2002;50:109–114.
- Donnenfeld E, O’Brien T, Solomon R, et al. Infectious keratitis after photorefractive keratectomy. Ophthalmology. 2003;110:743–747.
- Parmar P, Salman A, Kalavathy C, et al. Pneumococcal keratitis: A clinical profile. Clin Experiment Ophthalmol. 2003;31:44–47.
- Varaprasathan G, Miller K, Lietman T, et al. Trends in the etiology of infectious corneal ulcers at the F. I. Proctor Foundation. Cornea. 2004;23:360–364.
- Allan BD, Dart JK. Strategies for the management of microbial keratitis. Br J Ophthalmol. 1995;79:777–786.
- Sueke H, Kaye S, Neal T, et al. Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51:2519–2524.
- Johnson M, Hobden J, Hagenah M, et al. The role of pneumolysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res. 1990;9:1107–1114.
- Tweten RK. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun. 2005;73:6199–6209.
- Shumway CN, Klebanoff SJ. Purification of pneumolysin. Infect Immun. 1971;4:388–392.
- Briles DE, Nahm M, Schroer K, et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J Exp Med. 1981;153:694–705.
- Marquart ME, Monds KS, McCormick CC, et al. Cholesterol as treatment for pneumococcal keratitis: Cholesterol-specific inhibition of pneumolysin in the cornea. Invest Ophthalmol Vis Sci. 2007;48:2661–2666.
- Nandoskar M, Ferrante A, Bates E, et al. Inhibition of human monocyte respiratory burst, degranulation, phospholipid methylation and bactericidal activity by pneumolysin. Immunology. 1986;59:515–520.
- Ferrante A, Rowan-Kelly B, Paton JC. Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin. Infect Immun. 1984;46:585–589.
- Iliev AI, Djannatian JR, Nau R, et al. Cholesterol-dependent actin remodeling via RhoA and Rac1 activation by the Streptococcus pneumoniae toxin pneumolysin. Proc Natl Acad Sci U S A. 2007;104:2897–2902.
- Iliev A, Djannatian J, Opazo F, et al. Rapid microtubule bundling and stabilization by the Streptococcus pneumoniae neurotoxin pneumolysin in a cholesterol-dependent, non-lytic and Src-kinase dependent manner inhibits intracellular trafficking. Mol Microbiol. 2009;71:461–477.
- Watanabe I, Nomura T, Tominaga T, et al. Dependence of the lethal effect of pore-forming haemolysins of Gram-positive bacteria on cytolytic activity. J Med Microbiol. 2006;55:505–510.
- Hobden JA, Hill JM, Engel LS, et al. Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen. Antimicrob Agents Chemother. 1993;37:1856–1859.
- Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; approved standard, seventh edition. Clinical and Laboratory Standards Institute document M7-A7. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2006.
- Sanders M, Norcross E, Moore Q, et al. A comparison of pneumolysin activity and concentration in vitro and in vivo in a rabbit endophthalmitis model. Clin Ophthalmol. 2008;2:793–800.
- Price KE, Camilli A. Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J Bacteriol. 2009;191:2163–2168.